RepliCel Life Sciences【RP】銘柄情報

RepliCel Life Sciences Inc (RP) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.015

( - )

買値

0.01

売値

0.02

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

1.104M

前日終値

0.015

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

$ 26,131

発行済株式数

73,577,807

配当利回り

PER

-0.07

1 株当たり利益 (EPS)

-0

歳入

353.74k

純利益

-302.37k

0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate ag... 0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company’s product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy for aging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also involved in the developing DermaPrecise, a dermal injection device. 0913693 B.C. Ltd. has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize programs. The company was formerly known as RepliCel Life Sciences Inc. and changed its name to 0913693 B.C. Ltd. in March 2025. 0913693 B.C. Ltd. is based in Vancouver, Canada. 詳細を表示

セクター

業界

ウェブサイト

www.replicel.com

本社

Vancouver, Canada

設立

RepliCel Life Sciences Inc is listed in the sector of the トロントベンチャー取引所 with ticker RP. The last closing price for RepliCel Life Sciences was $0.02. Over the last year, RepliCel Life Sciences shares have traded in a share price range of $ 0.00 to $ 0.00.

RepliCel Life Sciences currently has 73,577,807 shares in issue. The market capitalisation of RepliCel Life Sciences is $1.10 million. RepliCel Life Sciences has a price to earnings ratio (PE ratio) of -0.07.